108 related articles for article (PubMed ID: 22605655)
1. Evaluation of responsive gene expression as a sensitive and specific biomarker in patients with ulcerative colitis.
Román J; Planell N; Lozano JJ; Aceituno M; Esteller M; Pontes C; Balsa D; Merlos M; Panés J; Salas A
Inflamm Bowel Dis; 2013 Feb; 19(2):221-9. PubMed ID: 22605655
[TBL] [Abstract][Full Text] [Related]
2. Safety and activity of dersalazine sodium in patients with mild-to-moderate active colitis: double-blind randomized proof of concept study.
Pontes C; Vives R; Torres F; Panés J
Inflamm Bowel Dis; 2014 Nov; 20(11):2004-12. PubMed ID: 25192498
[TBL] [Abstract][Full Text] [Related]
3. MMX mesalazine for the induction of remission of mild-to-moderately active ulcerative colitis: efficacy and tolerability in specific patient subpopulations.
Lichtenstein GR; Kamm MA; Sandborn WJ; Lyne A; Joseph RE
Aliment Pharmacol Ther; 2008 Jun; 27(11):1094-102. PubMed ID: 18363894
[TBL] [Abstract][Full Text] [Related]
4. MMX Multi Matrix System mesalazine for the induction of remission in patients with mild-to-moderate ulcerative colitis: a combined analysis of two randomized, double-blind, placebo-controlled trials.
Sandborn WJ; Kamm MA; Lichtenstein GR; Lyne A; Butler T; Joseph RE
Aliment Pharmacol Ther; 2007 Jul; 26(2):205-15. PubMed ID: 17593066
[TBL] [Abstract][Full Text] [Related]
5. Effect of extended MMX mesalamine therapy for acute, mild-to-moderate ulcerative colitis.
Kamm MA; Lichtenstein GR; Sandborn WJ; Schreiber S; Lees K; Barrett K; Joseph R
Inflamm Bowel Dis; 2009 Jan; 15(1):1-8. PubMed ID: 18671232
[TBL] [Abstract][Full Text] [Related]
6. Combined oral and enema treatment with Pentasa (mesalazine) is superior to oral therapy alone in patients with extensive mild/moderate active ulcerative colitis: a randomised, double blind, placebo controlled study.
Marteau P; Probert CS; Lindgren S; Gassul M; Tan TG; Dignass A; Befrits R; Midhagen G; Rademaker J; Foldager M
Gut; 2005 Jul; 54(7):960-5. PubMed ID: 15951542
[TBL] [Abstract][Full Text] [Related]
7. Balsalazide is superior to mesalamine in the time to improvement of signs and symptoms of acute mild-to-moderate ulcerative colitis.
Pruitt R; Hanson J; Safdi M; Wruble L; Hardi R; Johanson J; Koval G; Riff D; Winston B; Cross A; Doty P; Johnson LK
Am J Gastroenterol; 2002 Dec; 97(12):3078-86. PubMed ID: 12492193
[TBL] [Abstract][Full Text] [Related]
8. A randomized, double blind, dose-response comparison of balsalazide (6.75 g), balsalazide (2.25 g), and mesalamine (2.4 g) in the treatment of active, mild-to-moderate ulcerative colitis.
Levine DS; Riff DS; Pruitt R; Wruble L; Koval G; Sales D; Bell JK; Johnson LK
Am J Gastroenterol; 2002 Jun; 97(6):1398-407. PubMed ID: 12094857
[TBL] [Abstract][Full Text] [Related]
9. The role of centralized reading of endoscopy in a randomized controlled trial of mesalamine for ulcerative colitis.
Feagan BG; Sandborn WJ; D'Haens G; Pola S; McDonald JWD; Rutgeerts P; Munkholm P; Mittmann U; King D; Wong CJ; Zou G; Donner A; Shackelton LM; Gilgen D; Nelson S; Vandervoort MK; Fahmy M; Loftus EV; Panaccione R; Travis SP; Van Assche GA; Vermeire S; Levesque BG
Gastroenterology; 2013 Jul; 145(1):149-157.e2. PubMed ID: 23528626
[TBL] [Abstract][Full Text] [Related]
10. Curcumin in Combination With Mesalamine Induces Remission in Patients With Mild-to-Moderate Ulcerative Colitis in a Randomized Controlled Trial.
Lang A; Salomon N; Wu JC; Kopylov U; Lahat A; Har-Noy O; Ching JY; Cheong PK; Avidan B; Gamus D; Kaimakliotis I; Eliakim R; Ng SC; Ben-Horin S
Clin Gastroenterol Hepatol; 2015 Aug; 13(8):1444-9.e1. PubMed ID: 25724700
[TBL] [Abstract][Full Text] [Related]
11. Subcutaneous golimumab induces clinical response and remission in patients with moderate-to-severe ulcerative colitis.
Sandborn WJ; Feagan BG; Marano C; Zhang H; Strauss R; Johanns J; Adedokun OJ; Guzzo C; Colombel JF; Reinisch W; Gibson PR; Collins J; Järnerot G; Hibi T; Rutgeerts P;
Gastroenterology; 2014 Jan; 146(1):85-95; quiz e14-5. PubMed ID: 23735746
[TBL] [Abstract][Full Text] [Related]
12. Combined oral and rectal mesalazine for the treatment of mild-to-moderately active ulcerative colitis: rapid symptom resolution and improvements in quality of life.
Probert CS; Dignass AU; Lindgren S; Oudkerk Pool M; Marteau P
J Crohns Colitis; 2014 Mar; 8(3):200-7. PubMed ID: 24012063
[TBL] [Abstract][Full Text] [Related]
13. Randomised clinical trial: a herbal preparation of myrrh, chamomile and coffee charcoal compared with mesalazine in maintaining remission in ulcerative colitis--a double-blind, double-dummy study.
Langhorst J; Varnhagen I; Schneider SB; Albrecht U; Rueffer A; Stange R; Michalsen A; Dobos GJ
Aliment Pharmacol Ther; 2013 Sep; 38(5):490-500. PubMed ID: 23826890
[TBL] [Abstract][Full Text] [Related]
14. A [Glyco]biomarker that Predicts Failure to Standard Therapy in Ulcerative Colitis Patients.
Pereira MS; Maia L; Azevedo LF; Campos S; Carvalho S; Dias AM; Albergaria A; Lima J; Marcos-Pinto R; Lago P; Pinho SS
J Crohns Colitis; 2019 Jan; 13(1):39-49. PubMed ID: 30239648
[TBL] [Abstract][Full Text] [Related]
15. Double-blind comparative study of sulfasalazine and controlled-release mesalazine tablets in the treatment of active ulcerative colitis.
Munakata A; Yoshida Y; Muto T; Tsuchiya S; Fukushima T; Hiwatashi N; Kobayashi K; Kitano A; Shimoyama T; Inoue M
J Gastroenterol; 1995 Nov; 30 Suppl 8():108-11. PubMed ID: 8563868
[TBL] [Abstract][Full Text] [Related]
16. 3g mesalazine granules are superior to 9mg budesonide for achieving remission in active ulcerative colitis: a double-blind, double-dummy, randomised trial.
Gross V; Bunganic I; Belousova EA; Mikhailova TL; Kupcinskas L; Kiudelis G; Tulassay Z; Gabalec L; Dorofeyev AE; Derova J; Dilger K; Greinwald R; Mueller R;
J Crohns Colitis; 2011 Apr; 5(2):129-38. PubMed ID: 21453882
[TBL] [Abstract][Full Text] [Related]
17. Effect of once- or twice-daily MMX mesalamine (SPD476) for the induction of remission of mild to moderately active ulcerative colitis.
Lichtenstein GR; Kamm MA; Boddu P; Gubergrits N; Lyne A; Butler T; Lees K; Joseph RE; Sandborn WJ
Clin Gastroenterol Hepatol; 2007 Jan; 5(1):95-102. PubMed ID: 17234558
[TBL] [Abstract][Full Text] [Related]
18. Are endoscopic endpoints reliable in therapeutic trials of ulcerative colitis?
Wolff S; Terheggen G; Mueller R; Greinwald R; Franklin J; Kruis W
Inflamm Bowel Dis; 2013 Nov; 19(12):2611-5. PubMed ID: 24108110
[TBL] [Abstract][Full Text] [Related]
19. Randomised clinical trial: herbal extract HMPL-004 in active ulcerative colitis - a double-blind comparison with sustained release mesalazine.
Tang T; Targan SR; Li ZS; Xu C; Byers VS; Sandborn WJ
Aliment Pharmacol Ther; 2011 Jan; 33(2):194-202. PubMed ID: 21114791
[TBL] [Abstract][Full Text] [Related]
20. Association Between Response to Etrolizumab and Expression of Integrin αE and Granzyme A in Colon Biopsies of Patients With Ulcerative Colitis.
Tew GW; Hackney JA; Gibbons D; Lamb CA; Luca D; Egen JG; Diehl L; Eastham Anderson J; Vermeire S; Mansfield JC; Feagan BG; Panes J; Baumgart DC; Schreiber S; Dotan I; Sandborn WJ; Kirby JA; Irving PM; De Hertogh G; Van Assche GA; Rutgeerts P; O'Byrne S; Hayday A; Keir ME
Gastroenterology; 2016 Feb; 150(2):477-87.e9. PubMed ID: 26522261
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
